Aetion, the global leader in real-world evidence (RWE) technology and analytics, has officially confirmed that its Aetion® Evidence Platform (AEP) is now available on Amazon Web Services (AWS) Marketplace, which happens to be a digital catalog with thousands of software listings from independent software vendors.
According to certain reports, the stated development should tread up a long distance in the context of eliminating implementation barriers, simplifying procurement, as well as empowering life sciences organizations, payers, and regulators to access scalable, cloud-based evidence generation with the security and reliability of AWS.
More on the AWS bit would reveal how AEP banks upon it to access cutting-edge services like Amazon Bedrock, services that have proven useful for supporting the company’s artificial intelligence and machine learning (AI/ML)-driven capabilities. The overarching idea behind creating such a setup is to unlock hidden insights regarding patient populations and translate scientific intent to concrete results.
Anyway, having AWS in the mix makes it possible for AEP’s ability to help organizations analyze real-world data (RWD). Once the stated analysis has been duly finished, users can leverage the results to eventually generate transparent, reproducible and regulatory-grade evidence for decision-making in drug development, market access, policy, and pricing.
All in all, Aetion deploys AWS to streamlines access of its platform and reliable, fit-for-purpose solutions that, on their part, are tailored to meet each organization’s specific objectives, accelerate time-to-insights, and ensure compliance with global regulatory standards.
Taking a deeper view of how AEP’s availability on AWS Marketplace will go on to benefit customers, we begin from the potential for seamless procurement. You see, as AWS Marketplace simplifies contracting and billing, it should allow for users to access AEP at a much faster clip than ever before.
Next up, there is the promise of scalability and performance. This includes AEP’s AWS undertones making it possible for the solution to bring a cloud-native infrastructure in use when handling large-scale real-world data analysis.
Another detail worth a mention here is rooted in the prospect of compliance and security. In essence, AEP operates within the secure AWS environment, meaning the solution is fully-aligned with HIPAA, GDPR, and 21 CFR Part 11 regulatory requirements.
A by-product of its access to AWS ecosystem, the move will also help AEP seamlessly integrate AI/ML services and analytics tools into its fabric, something which should significantly enhance the available data-driven insights.
Founded in 2012, Aetion’s rise up the ranks stems from applying validated epidemiologic methods, causal inference, and structured analytics to transform real-world data (RWD) into decision-grade insights. The company’s proprietary platform, at the moment, supports predictive analytics, personalized treatment strategies, and scalable solutions for regulatory submissions, market access and clinical development.
Aetion’s excellence in what it does can also be understood once you consider it is trusted a host of different parties, including biopharma companies, medical device manufacturers, payers, and regulators.
“The availability of AEP in AWS Marketplace underscores our commitment to providing scalable, high-impact solutions that help organizations make real-world data work for them,” said Jay Podence, senior vice president, Commercial Partnerships, Aetion. “By integrating with AWS, we offer our new and existing customers a seamless path to deploy and scale real-world evidence studies with enhanced efficiency and security. This is the first step in our vision to expand our collaboration with AWS to bring more value to our customers. Ultimately, our goal is to deliver an end-to-end real-world evidence platform that fully integrates with the customer’s AWS-owned instances.”
